A similar pattern was observed for the Immunity2 metagene (HER2-negative-ER positive: 16.5% versus 8.1%, OR = 2.22, p = 0.05), HER2-positive (45.5% versus 18.7%, OR = 3.57, p = 0.01), and TNBC breast cancers (36.3 versus 24.6%, OR = 1.75, p = 0.08; S3B Fig), but the difference was not statistically significant (p = 0.08) in the TNBC subgroup. Here, ERBB2 is linked to breast carcinoma.